Search results
Results from the WOW.Com Content Network
StemCell Technologies Canada Inc. (formerly known as StemCell Technologies Inc.) is a Canadian biotechnology company that develops and manufactures cell culture media and cell separation technologies for use in stem cell, immunology, and cancer research. [1] [2]
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis.
Astellas Institute for Regenerative Medicine is a subsidiary of Astellas Pharma located in Marlborough, Massachusetts, US, developing stem cell therapies with a focus on diseases that cause blindness. It was formed in 1994 as a company named Advanced Cell Technology, Incorporated (ACT), which was renamed to Ocata Therapeutics in November 2014. [3]
STEMCELL Technologies Inc supports Canada's Networks of Centres of Excellence (NCE) Program, including: the Stem Cell Network where STEMCELL Technologies Inc is the major corporate supporter and Eaves is a member of the Board, and the Mathematics of Information Technology and Complex Systems, Mitacs Inc. where Eaves previously served as ...
Stem cell therapeutic products Dual listed on TASE RADA Electronic Industries Ltd. RADA: 1985 Aerospace Radcom Ltd. RDCM: 1997 Networking & communication Part of the RAD Group Radware Ltd. RDWR: 1999 Networking & communication Part of the RAD Group RedHill Biopharma Ltd. RDHL 2013 Biopharmaceutical Gastrointestinal treatment ReWalk: RWLK: 2014
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
WiCell Research Institute is a scientific research institute in Madison, Wisconsin that focuses on stem cell research. Independently governed and supported as a 501(c)(3) organization, WiCell operates as an affiliate of the Wisconsin Alumni Research Foundation and works to advance stem cell research at the University of Wisconsin–Madison and beyond.
Geron Corporation has sponsored human clinical trials of several potential anti-cancer products. Imetelstat (GRN163L) is a drug that targets telomerase. [13] In studies conducted at Johns Hopkins University, GRN163L was active against both CD138+ and CD138neg cancer stem cells and eliminated the colony forming potential of both by five weeks. [14]